Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Hepatic Impairment (HI): early-phase trial registry

2 of 2 indexed Hepatic Impairment (HI) trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Hepatic Impairment (HI): 2 US clinical trials tracked, 2 recruiting.

Hepatic Impairment (HI) is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Edgewise Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition hepatic-impairment-hi

OPEN 2 | RECR 100% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Hepatic Impairment (this)100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hepatic Impairment (HI)

Hepatic Impairment (HI) lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hepatic Impairment (HI) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hepatic Impairment (HI) is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Named interventions

Most-linked intervention names on Hepatic Impairment (HI) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

EDG-7500 Drug
1 trials
Nemtabrutinib Drug
1 trials

US sites by state

Facility locations filed on Hepatic Impairment (HI) trials. A trial with sites in several states counts in each.

Florida 2 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hepatic Impairment (HI) page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Hepatic Impairment (HI) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Edgewise Therapeutics sponsors the most Hepatic Impairment (HI) trials on record, review their full trial history before evaluating a specific study. See Edgewise Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatic Impairment (HI) condition card totals 2 registered trials; most-linked intervention EDG-7500; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.